While fever prevention for 72 hours after cardiac arrest has been endorsed by international guidelines since 2005, there is a lack of randomized control trial (RCT) generated data supporting this after the initial 24 hours of temperature control.

The authors of this RCT found that active device-based fever prevention for 36 or 72 hours after cardiac arrest did not result in significant different percentages of patients dying or having severe disability or coma within 90 days.

802 patients were enrolled from March 2017-December 2021. The intention-to-treat population consisted of 789 patients, 393 patients were assigned to 36 hours and 396 patients were assigned to 72 hours of device-based-temperature control.

Read More